The firms originally inked the agreement in 2015 and have now extended it until 2025.
The deal is expected to close by the end of 2018 and to contribute between $40 million and $50 million in revenues to Luminex in 2019.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
Universities and research institutes are making CRISPR/Cas9 more accessible than ever through new and existing core facilities.
Sales for the firm's life science segment jumped 25 percent year over year to €3.36 billion from €2.68 billion.
After falling for three years in a row, mergers and acquisitions in the omics space rose sharply in 2015, driven by a few billion-dollar-plus deals.
The deal creates a science sector giant able to "cover every step of the biotech production chain."
The firm expects its acquisition by Merck KGaA to be completed this month.
Based on Olink's proximity ligation technology, Duolink allows for detection of low-abundance proteins with higher specificity than conventional immunoassays.
Sigma-Aldrich will participate in the university's Catalyst Program, which is designed to support translation of early biomedical discoveries into commercial products.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.